Tamoxifen: the drug that came in from the cold.

Full Abstract

Despite the perception of many oncologists that tamoxifen is an inferior drug, and should be substituted by an aromatase inhibitor in post-menopausal women, the current evidence strongly supports the view that AIs should be used 2-3 years after tamoxifen to achieve the maximal overall survival (OS) advantage.

Author information

Author/s: Hughes-Davies, L (L); Caldas, C (C); Wishart, G C (GC);

Affiliation: Cambridge Breast Unit, Addenbrooke's Hospital, Hills Road, Cambridge, UK.

Journal and publication information

Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review

Journal: British journal of cancer (Br J Cancer), published in England. (Language: eng)

Reference: 2009-Sep; vol 101 (issue 6) : pp 875-8

Dates: Created 2009/09/09; Completed 2009/09/23; Revised 2009/10/28;

PMID: 19672259, status: MEDLINE (last retrieval date: 10/29/2009, IMS Date: )

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article
(including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.